CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]drug
Likely dose
Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01523821
NCT01523821Phase 2Completed
CompareCT.gov

Treatment of Steroid Non-responsive Acute GVHD With Alpha 1 Antitrypsin (AAT). A Phase I/II Study

Fred Hutchinson Cancer Center·interventional·Posted Feb 1, 2012·Updated Oct 30, 2018

In Brief

A Phase 2 clinical trial evaluating Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia] for Graft-Versus-Host Disease (GVHD) Acute on Chronic. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This phase I/II trial evaluates the efficacy and adverse effects of alpha 1 anti-trypsin (AAT) for the treatment of acute graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft-Versus-Host Disease (GVHD) Acute on Chronic
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 1, 2012
Enrollment StartOct 11, 2013
Primary CompletionJan 15, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.4 years ago

Interventions

Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]drug

Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days